Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3B Study of Etrolizumab-Based Induction Combinations Followed by Etrolizumab Maintenance in Moderate-to-Severe Ulcerative Colitis
2019-004652-11Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Etrolizumab in autoimmune colitis (4 arms), sponsored by Roche. Started Aug 2020; status: completed.
02
Drugs
Etrolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2019-004652-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004652-11.